Opko Health Inc. (NASDAQ:OPK)’s share price reached a new 52-week low on Monday . The stock traded as low as $2.32 and last traded at $2.33, with a volume of 150621 shares changing hands. The stock had previously closed at $2.40.

Several brokerages have commented on OPK. Zacks Investment Research downgraded Opko Health from a “buy” rating to a “hold” rating in a research report on Monday, February 4th. ValuEngine raised Opko Health from a “sell” rating to a “hold” rating in a research report on Wednesday, January 2nd. Finally, Barrington Research reaffirmed a “buy” rating and issued a $5.00 price objective on shares of Opko Health in a research report on Thursday, February 28th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Opko Health currently has an average rating of “Buy” and an average price target of $9.67.

The stock has a market cap of $1.47 billion, a P/E ratio of -9.36 and a beta of 1.88. The company has a quick ratio of 0.96, a current ratio of 1.10 and a debt-to-equity ratio of 0.03.

Opko Health (NASDAQ:OPK) last announced its quarterly earnings data on Wednesday, February 27th. The biotechnology company reported ($0.08) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.09) by $0.01. The company had revenue of $221.90 million for the quarter, compared to the consensus estimate of $242.05 million. Opko Health had a negative return on equity of 7.69% and a negative net margin of 15.46%. On average, equities analysts predict that Opko Health Inc. will post -0.2 earnings per share for the current year.

In other news, CEO Phillip Md Et Al Frost bought 200,000 shares of the stock in a transaction on Thursday, February 28th. The stock was acquired at an average cost of $2.48 per share, for a total transaction of $496,000.00. Following the acquisition, the chief executive officer now owns 3,068,951 shares of the company’s stock, valued at $7,610,998.48. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Vice Chairman Jane Ph D. Hsiao bought 10,000 shares of the stock in a transaction on Thursday, January 31st. The stock was purchased at an average price of $7.96 per share, with a total value of $79,600.00. Following the completion of the acquisition, the insider now directly owns 24,455,147 shares in the company, valued at approximately $194,662,970.12. The disclosure for this purchase can be found here. Insiders acquired a total of 798,000 shares of company stock worth $2,032,580 in the last ninety days. 42.74% of the stock is currently owned by corporate insiders.

Several hedge funds have recently modified their holdings of the business. BlackRock Inc. lifted its holdings in shares of Opko Health by 1.4% in the 4th quarter. BlackRock Inc. now owns 30,276,662 shares of the biotechnology company’s stock worth $91,133,000 after buying an additional 408,951 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Opko Health by 2.1% in the 3rd quarter. Vanguard Group Inc. now owns 29,660,750 shares of the biotechnology company’s stock worth $102,626,000 after buying an additional 614,442 shares during the period. Vanguard Group Inc lifted its holdings in shares of Opko Health by 2.1% in the 3rd quarter. Vanguard Group Inc now owns 29,660,750 shares of the biotechnology company’s stock worth $102,626,000 after buying an additional 614,442 shares during the period. Dimensional Fund Advisors LP lifted its holdings in shares of Opko Health by 25.3% in the 3rd quarter. Dimensional Fund Advisors LP now owns 4,440,784 shares of the biotechnology company’s stock worth $15,363,000 after buying an additional 897,406 shares during the period. Finally, Geode Capital Management LLC lifted its holdings in shares of Opko Health by 4.2% in the 4th quarter. Geode Capital Management LLC now owns 4,078,397 shares of the biotechnology company’s stock worth $12,275,000 after buying an additional 165,517 shares during the period. Institutional investors and hedge funds own 23.10% of the company’s stock.

WARNING: “Opko Health (OPK) Hits New 12-Month Low at $2.32” was posted by Watch List News and is owned by of Watch List News. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this story can be accessed at https://www.watchlistnews.com/opko-health-opk-hits-new-12-month-low-at-2-32/2981466.html.

About Opko Health (NASDAQ:OPK)

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories, a clinical laboratory that offers laboratory testing services.

Featured Story: What are municipal bonds?

Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.